Perceptive

Perceptive is a leading global technology-enabled service provider for preclinical and clinical trial imaging and IRT/RTSM (Interactive Response Technology/Randomized Trial Supply Management). The company emerged in September 2024 when Calyx and Invicro rebranded under a unified identity, combining over 50 years of specialized experience in the clinical research industry.

The company empowers pharmaceutical, biotech, and clinical research organizations to rapidly discover and advance life-changing medicines across the complete R&D lifecycle. Perceptive operates through three integrated divisions: Perceptive Discovery, offering preclinical and translational imaging services including radiochemistry and in vivo imaging; Perceptive eClinical, providing cloud-based randomization and trial supply management platforms and electronic clinical outcome assessments; and Perceptive Imaging, functioning as an independent imaging core laboratory for clinical trials worldwide.

With operations spanning the US, Europe, UK, and Asia, Perceptive has supported nearly 12,000 clinical trials and over 800 regulatory approvals. The company maintains embedded clinical and imaging centers at prestigious academic institutions including Imperial College London and Barts Cancer Institute, enabling first-in-human imaging capabilities. Their expertise concentrates on oncology, neuroscience, radiopharmaceutical therapy, and rare diseases, serving most of the world's leading pharmaceutical and biotech companies with 24/7 service delivery.